3D Tissue Models

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2013 TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases. Cancer Gene Therapy 2013;20:65-69
2. 2013 Laparoscopic left lateral sectionectomy with the use of the Habib 4X: Technical aspects. Journal of Laparoscopic & Advanced Surgical Techniques 2013;23:1-4
3. 2013 Reactive lymphoid hyperplasia of the pancreas: a clinical conundrum. Journal of the Pancreas 2013;14:207-211
4. 2012 Does neostigmine improve time to resolution of symptoms in acute colonic pseudo-obstruction? International Journal of Surgery 2012;10:453-457
5. 2012 Novel percutaneous radiofrequency ablation of portal vein tumor thrombus: Safety and feasibility. Cardiovascular Interventional Radiology August 2012
6. 2012 Tumor infiltration in the medial resection margin predicts survival after pancreaticoduodenenctomy for pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery 2012;16:1875-1882
7. 2012 The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolisation: comparison with RECIST and tumour density criteria. European Journal of Nuclear Medicine Molecular Imaging 2012;39:1391-1399
8. 2012 Gene expression profile changes after short-activating RNA-meidated induction of endogenous pluripotency factors in human mesenchymal stem cells. Molecular Therapy-Nucleic Acidson line publication 07 August 2012
9. 2012 Micro-RNA-181a* targets nanog in a subpopulation of CD34+ cells isolated from peripheral blood. Molecular Therapy-Nucleic Acidson line publication 07 August 2012
10. 2012 A new endovascular radiofrequency device for dilatation of vascular stenosis in a rabbit model. J Invest Surg 2012;25:253-261
11. 2012 18F-fluorodeoxyglucose postiron emission tomography in management of pancreatic cystic tumours. Nucl Med Biol 2012;39:982-985
12. 2012 MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumours. PLoS One 2012;7:e32068
13. 2012 Evaluation of effects of novel endoscipically applied radiofrequency ablation biliary catheter using ex-vivo pig liver. Journal of Hepato-Biliary-Pancreatic Sciences 2012;19:543-547
14. 2012 Autologous bone marrow stem cells in chronic liver disease. International Journal of Hepatology 2012;2012:307165
15. 2012 Radiofrequency assisted liver resection: Analysis of 604 consecutive cases. European Journal Of Surgical Oncology 2012;38:274-280
16. 2012 Is early laparoscopic cholecystectomy for acut cholecystitis preferable to delayed surgery? International Journal of Surgery 2012;10:250-258
17. 2012 A perspective on non-catalytic Src homology (SH) adaptor signalling proteins. Cell Signalling 2012;24:388-392
18. 2012 Use of bipolar radiofrequency in parenchymal transaction of the liver, pancreas and kidney. Digestive SurgeryREVIEW
19. 2012 Laparoscopic resection of a giant exophytic liver haemangioma with the laparoscopic Habib 4X radiofrequency device. World Journal of Gastrointestinal Surgery 2012;27:199-202
20. 2011 Endoscopically applied radiofrequency ablation appears safe in the treatment of malignant biliary obstruction Gastrointestinal Endoscopy. 2011;73:149-153
21. 2011 Intracellular adaptor molecules and AR signalling in the tumour microenvironment. Cell Signalling 2011;25:1017-1021
22. 2011 Experimental animal study of a novel radiofrequency endovascular occlusion device. American Journal of Surgery 2011;201:103-109
23. 2011 A novel experimental model of arterial stenosis based on endovascular radiofrequency energy application. Journal of Investigative Surgery 2011;24:123-128
24. 2011 Minimal invasive technique for gene delivery in porcine liver lobe segment. Journal of Investigative Surgery 2011;24:13-17
25. 2011 Embolisation of hepatic arterial branches to simplify hepatic blood flow before Yttrium 90 radioembolisation: A useful technique in the presence of challenging anatomy. Cardiovascular Interventional Radiology 2011;34:287-294
26. 2011 Two stage resection for bilobar colorectal liver metastases: R0 resection is the key. Annals of Surgical Onoclogy5 epub
27. 2010 Concerns about ultrasound-guided radiofrequency-assisted segmental liver resection. Letter. Annals of Surgery 2010;251:1192
28. 2010 Human stem cell therapy in ischaemic stroke: a review. Age and Ageing 2010;40:1-7
29. 2010 Adenovirus 5-Fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia. Human Gene Therapy 2010;23
30. 2010 Surgical treatment for liver cancer. World Journal of Gastroenterology 2010;16:927-933
31. 2010 Interaction between AR signalling and CRKL bypasses casodex inhibition in prostate cancer. Cell Signalling 2010:22:1874-81
32. 2010 Impact of portal vein embolisation on expression of cancer stem cell markers in regenerated liver and colorectal liver metastases. Scandinavian Journal of Gastroenterology 2010;45:1472-1479
33. 2010 Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer. Pancreas 2010;39:897-903
34. 2009 Unique localization of circulating tumor cells in patients with hepatic metastases. Journal of Clinical Oncology 2009;27:6160-6165
35. 2009 Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of clinicopathological factors. Journal of Surgical Oncology 2009;15:651-656
36. 2009 Cytsic tumors of the biliary tract: a complete excision is crucial. International Surgery 2009;94:136-40
37. 2009 Ultrasound-guided radiofrequency-assisted segmental liver resection: a new technique. Annals of Surgery 2009:250:229-233
38. 2009 Initial data on a novel endovascular radiofrequency catheter when used for arterial occlusion in liver cancer. European Surgery 2009;41:104-108
39. 2009 Pilot study for a new bipolar radiofrequency ablation/aspirator device in the management of primary and secondary liver cancers. Liver International 2009;824-830
40. 2009 Potential uses of microRNA in lung cancer diagnosis, prognosis and therapy. Current Cancer Drug Targets 2009;9:572-594
41. 2009
42. 2009 Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs Journal of Translational Medicine 2009;7:18
43. 2009 Endoscopic radiofrequency ablation in colorectal cancer: Initial clinical results of a new bipolar radiofrequency ablation device. Diseases of the Colon & Rectum 2009;52:355-358
44. 2009 Domino liver transplantation using a graft from a donor with familial hypercholesterolaemia: Seven year follow-up. Clinical Transplantation 2009;23:565-570
45. 2008 High frequency of fetal cells within a primitive stem cell population in maternal blood. Human Reproduction 2008;23:928-933
46. 2008 Radiofrequency-assisted liver resection in patients with hepatocellular carcinoma and cirrhosis: preliminary results. Transplant Proceedings 2008;40:3523-3525
47. 2008 The phosphorylated membrane estrogen receptor and cytoplasmic signalling and apoptosis proteins in human breast cancer. Cancer 2008;113:1489-1495
48. 2008 Management of delayed arterial hemorrhage after pancreatoduodenectomy. A case series. Journal of the Pancreas 2008;9:172-178
49. 2008 Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Therapy 2008;15:225-230
50. 2008 Preoperative portal vein embolization for major liver resection. A meta-analysis. Annals of Surgery 2008;248:49-57
51. 2008 Management of delayed postoperative haemorrhage after pancreaticoduodenectomy. A meta-analysis. Archives of Surgery(Review)
52. 2008 Laparoscopic Habibtrade mark 4X: a bipolar radiofrequency device for bloodless laparoscopic liver resection. HPB (Oxford) 2008;10:261-264
53. 2008 Liver resection with bipolar radiofrequency device: Habib trade mark 4X. HPB (Oxford) 2008;10:256-260
54. 2008 Radiofrequency-assisted liver resection in cirrhotic patients with hepatocellular carcinoma. Journal of Surgical Oncology 2008;98:407-410
55. 2008 Autologous infusion of expanded mobilized adult bone marrow derived CD34+ cells into patients with alcoholic liver cirrhosis. American Journal of Gastroenterology 2008;103:1952-1958
56. 2008 Repeat Hepatic Resection using a Radiofrequency Assisted Technique. Digestive Surgery 2008;25:293-299
57. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs
58. BACKGROUND: Despite careful patient selection and preoperative investigations curative resection rate (R0) in pancreaticoduodenectomy ranges from 15% to 87%. Pubmed BACKGROUND: Despite careful patient selection and preoperative investigations curative resection rate (R0) in pancreaticoduodenectomy ranges from 15% to 87%. Here we describe a new palliative approach for pancreaticoduodenectomy using a radiofrequency energy device to ablate tumor in situ in patients undergoing R1/R2 resections for locally advanced pancreatic ductal adenocarcinoma where vascular reconstruction was not feasible. RESULTS: There was neither postoperative mortality nor significant morbidity. Each time the ablation lasted less than 15 minutes. Following radiofrequency ablation it was observed that the tumor remnant attached to the vessel had shrunk significantly. In four patients this allowed easier separation and dissection of the ablated tumor from the adherent vessel leading to R1 resection. In the other two patients, the ablated tumor did not separate from vessel due to true tumor invasion and patients had an R2 resection. The ablated remnant part of the tumor was left in situ. CONCLUSION: Whenever pancreaticoduodenectomy with R0 resection cannot be achieved, this new palliative procedure could be considered in order to facilitate resection and enable maximum destruction in remnant tumors. METHOD: Six patients with suspected tumor infiltration and where vascular reconstruction was not warranted underwent radiofrequency-assisted pancreaticoduodenectomy for locally advanced pancreatic ductal adenocarcinoma. Radiofrequency was applied across the tumor vertically 5-10 mm from the edge of the mesenteric and portal veins. Following ablation, the duodenum and the head of pancreas were removed after knife excision along the ablated line. The remaining ablated tissue was left in situ attached to the vessel. palliation; pancreatic ductal adenocarcinoma; pancreaticoduodenectomy; radiofrequency ablation
59. Background: Malignant biliary and/or pancreatic obstruction has often encountered in the advanced stages of periampullary and cholangicarcinomas. Pubmed Background: Malignant biliary and/or pancreatic obstruction has often encountered in the advanced stages of periampullary and cholangicarcinomas. HabibTM Radiofrequency (RF) ablation has been successfully used in the management of various cancers of liver and pancreas. Percutaneous HPB probe (EMcision Ltd, London, UK) is a new addition to this class of tools. It is an endoluminal Radiofrequency (RF) catheter which works on the principle of ablation and induces coagulative necrosis to recanalize the obstructed duct. The aim of this study is to address the technical details of canalization, feasibilities and outcomes of percutaneous endo-luminal Radiofrequency (RF) catheter in patients with unresectable malignancy with obstructed bile and pancreatic duct (PD). Material and Method: A total of 134 patients with inoperable malignant obstruction of biliary and PD underwent RF based percutaneous endoluminal RF ablation in a tertiary referral centre between December 15th, 2010 to August 7th, 2015. This device was used in a sequential manner with an intent to recanalize the obstructed. Following the initial catheter drainage of the duct, subsequent percutaneous endobiliary RF ablation, the metallic stent was placed to recanalize the obstructed bile and PD secondary to unresectable malignancy under real-time fluoroscopic guidance. Results: The percutaneous RF based ablation of obstructed bile duct and PD with metallic stent placement was successfully achieved in 130 (97.01%) cases. The three failures were noted in cases of biliary obstruction whilst, one with PD obstruction. The patency restored in 124 and patients, where the procedure was successfully completed and revealed clinical improvement reported. Conclusion: The percutaneous endoluminal RF based ablation of obstructed duct with metallic stent placement appeared to be a safe, effective procedure and may improve survival in patients with advanced stage cancer presenting with biliary and PD obstruction. Considering the above mentioned evidence, this modality may stand ahead of stenting alone. This could be considered as viable modality in management of such patients where very limited treatment options are available. biliary obstruction; cholangiocarcinoma; pancreatic adenocarcinoma; pancreatic duct obstruction; percutaneous; radiofrequency ablation
60. BACKGROUND: The aim of this study was to evaluate the oncological outcomes of hepatocellular carcinoma patients undergoing liver resection using cavitron ultrasonic surgical aspirator (CUSA) or radiofrequency (RF) based device Habib-4X. Pubmed BACKGROUND: The aim of this study was to evaluate the oncological outcomes of hepatocellular carcinoma patients undergoing liver resection using cavitron ultrasonic surgical aspirator (CUSA) or radiofrequency (RF) based device Habib-4X. . STUDY DESIGN: We prospectively analyzed the data of 280 patients who underwent liver resection for hepatocellular carcinoma at our institution from 2010-2012 with follow up till August 2016. The CUSA was used in the 163 patients whilst Habib-4X in 117 patients. The end points of analysis were oncological outcomes as disease recurrence, disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method, which has been compared with all other existing literature on the survival study. RESULTS: Compared with CUSA the reported incidence of recurrence was significantly lower, in Habib-4X group; p < 0.01. The median DFS was significantly better in Habib-4X group than CUSA group (50.80 vs 45.87 months, p = 0.03). The median OS was better in Habib-4X group than CUSA group (60.57 vs 57.17 months, p = 0.12) though the lesser difference in OS between the groups might be explained by the use of palliative therapies as TACE, percutaneous RFA, etc. in case of recurrence. CONCLUSIONS: RF based device Habib-4X, is safe and effective device for resection of hepatocellular carcinoma, in comparison to CUSA with better oncological outcomes, i.e., significantly lesser tumour recurrence and better DFS. This could be explained on the basis of systemic and local immunomodulatory effect involving induction of kupffer cells and effector CD-8 T cells that help in minimizing postoperative complications and bring more advantageous oncological outcomes. hepatocellular cancer; liver resection


About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.